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Abstract 
 
         Obesity results from prolonged positive imbalance between energy in take and expenditure. When food intake 
chronically exceeds the body’s energy need, an efficient metabolism results in the storage of the excess energy as fat. 
Mitochondria are the main centre for energy production in eukaryotic cells. Mitochondrial proton cycling is responsible for a 
significant proportion of basal or standard metabolic rate, therefore, further uncoupling of mitochondria may be a good way 
to increase energy expenditure and hence represent a good pharmacological target for the treatment of obesity. This implies 
that, any chemical agent or photochemical compound that further uncouples the mitochondria in vivo without having any 
effect on mitochondria activity could be a potential target in finding treatment for obesity. In the past, uncoupling by 2, 4-
dinitrophenol has been used this way with notable success. This paper discusses the mitochondria as targets in the discovery 
of potential plant natural anti-obesity products from Africa’s rich rainforests. 
 
Key words: Uncoupling, Mitochondria, Pharmacology, Medicinal Plants, Obesity. 
 
 
 
Obesity: The Disease, Control and Treatment  
 
         Obesity is a metabolic condition resulting from prolonged positive imbalance between energy intake and expenditure 
leading to the storage of excess calories as fat. An individual is said to be obese when that person is too fat for his or her 
well-being (Prentice, 2005; Puhl and Brownell, 2001). Technically, obesity is where the Body Mass Index (BMI) is above 
30kg/m2. This condition, which was once thought to be a problem confronting developed countries, is fast becoming a global 
issue and a major public health problem in developing countries. In the latter, the situation is even more complicated by the 
co-existence of obesity with malnutrition making it extremely difficult to control (Prentice, 2006).  
         The rapidly increasing worldwide incidence of obesity and its association with serious comorbid diseases such as type 
II diabetes means it is beginning to replace other nutrition and infectious diseases as the most significant contributor to ill 
health (Kopelman, 2000). As a matter of fact, participants at the first International Association for the Study of Obesity 
(IASO) meeting in Sun City, South Africa cited obesity to be becoming epidemic in the developing world. According to 
them, obesity is now a major disease in Africa, along with HIV - AIDS and malnutrition and that in South Africa, one in 
three men and more than one in two adult women are overweight and obese, while in Morocco 40% of the population are 
overweight. Cultural and societal factors coupled with lack of exercise and unhealthy diets explain the rising prevalence. A 
call was made for urgent action to combat the epidemic in order to prevent chronic diseases linked to obesity, which 
ultimately slows down economic development in developing countries. 
         Weight loss, induced by dieting, has been shown to be successful in reducing the health consequences of obesity but 
unfortunately more than 90% of individuals who lose weight through dietary control eventually return to their original weight 
(Waden, 1993). Pharmacological treatment may therefore be desirable for patients with associated comorbid conditions who 
have been unable to control their obesity through diet and exercise. Any treatment for obesity has to reduce energy intake, 
increase energy expenditure or combine both effects. Current therapies for obesity predominantly lead to decreased energy 
intake either by acting at satiety centres in the brain (e.g. sibutramine) (Bray et al., 1999; James et al., 2000; Ryan, 2000), by 
reducing the efficiency of intestinal absorption (e.g. orlistat) (Sjostrom et al., 1998; Hvizdos and Markham, 1999) or by 
reducing appetite (e. g. rimonabant).  
         Exercise is the most practical and most potentially easiest way to increase energy expenditure. Studies have shown a 
sevenfold increased risk of the incidence of overweight in those with a physical activity ratio (total energy expenditure: 
resting metabolic rate) of <1.8 (Ferro-Luzzi and Martino, 1996). The main benefit of exercise is to increase metabolic rate, 
and overall energy expenditure, by a greater amount than that resulting directly from exercise (Poehlamn, 1989). 
Pharmacological agents that increase metabolic rate are likely to mimic this beneficial effect of exercise on resting metabolic 
rate and could provide a useful adjunct to agents acting to reduce satiety; this review will discuss how targeting 
mitochondrial uncoupling will help discover such potential plant natural products from Africa’s rich rainforests. 
 
Uncoupling of mitochondria as a viable target for the development of anti-obesity drugs 
 
         Mitochondria are normally responsible for 90% of cellular oxygen consumption and the majority of adenosine  
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triphosphate (ATP) production (Kennedy and Lehninger, 1949). According to the chemiosmotic theory, the flow of electrons 
from reduced substrate to oxygen is coupled by a proton electrochemical gradient across the mitochondrial inner membrane 
to the synthesis of ATP from adenosine diphosphate (ADP) and phosphate (Mitchell, 1961). This process of oxidative 
phosphorylation can be subdivided into two distinct parts: the generation of the proton electrochemical gradient by the 
respiratory chain and the synthesis of ATP by the F0-F1 ATP synthase using the potential energy stored in the gradient 
(Harper et al., 2001). Naturally, not all the protons will find their way through the ATPase: some will go via other available 
pathways and will therefore not be used for ATP synthesis. This means that, not all of the available energy is coupled to ATP 
synthesis; instead, much is by uncoupled reactions when protons move from the cytosol back into the mitochondrial matrix 
via pathways which circumvent the ATP synthase and the other uses of the electrochemical gradient.  
         The importance of mitochondrial uncoupling as a potential target for finding therapeutic treatment for obesity has been 
extensively reviewed elsewhere (Brand, 2005; Harper et al., 2001). By simple deduction, when food intake chronically 
exceeds the body’s energy need, an efficient metabolism results in the storage of the excess energy as fat consequently 
leading to weight gain and obesity. Therefore decreasing metabolic efficiency by increasing mitochondrial uncoupling will be 
an effective way to increase basal metabolic rate and can lead to a substantial reduction in body weight by loss of fat 
deposits. This uncoupling of mitochondria represents a particularly attractive target and there is already excellent proofs of 
the concept for this approach in humans using 2,4-dinitrophenol (DNP) (Parascandola, 1974) and in animals using  -
adrenoceptor agonists (Weyer et al., 1999), over expression of UCP1 (uncoupling protein 1) (Li et al.. 2000) or  UCP3 
(Clapham et al., 2000).  
         Consequently, using pharmacological agents to uncouple all mitochondria throughout the body may be a high-risk 
treatment, because it might compromise energy homeostasis in tissues such as heart and brain. On the other hand, active 
tissues like these may be less susceptible to mild uncoupling than less active ones like resting muscle or resting BAT because 
proton conductance has much less control over respiration rate in active mitochondria (Hafner, et al., 1990). The small 
difference between the effective and the fatal doses of DNP, as well as side-effects resulting from its non-selective actions 
(Parascandola, 1974), implies that it is not in itself a suitable anti-obesity drug. Tissue selectivity and safety need to be 
improved for full effectiveness.  
         The UCP3-overexpressing mouse shows that selective uncoupling of muscle mitochondria is sufficient for a strong anti-
obesity effect. Specific uncoupling of brown adipose tissue mitochondria through UCP3 or in some other way remains a 
viable and attractive target for the development of drugs for the treatment of obesity. 
Skeletal muscle represents a particularly attractive target for directed uncoupling due to the large muscle mass, which 
accounts for approximately 15-20% of standard metabolic rate (Rolfe and Brand, 1996; Rolfe et al., 1999). Doubling 
metabolic rate by modestly uncoupling skeletal muscle should produce few adverse side effects as this increase would only 
be equivalent to mild exercise (actually equivalent to approximately the difference between lying down and standing up 
(Blaxter, 1989). Indeed support for this view has been obtained using proteins that may naturally uncouple mitochondria 
(uncoupling proteins 1 and 3). High expression of human UCP3 in mouse skeletal muscle led to decreased weight gain 
despite increased food intake (Clapham et al., 2000), and expression of UCP1 in mouse skeletal muscle led to improvements 
in insulin sensitivity and resistance to obesity on a high fat diet (Li et al., 2000).  
 
Mitochondrial Uncouplers  
 
         As illustrated above, the discovery of natural mitochondrial uncouplers with wide therapeutic window and high tissue 
specificity for the treatment of obesity has become a major challenge preoccupying most research and pharmaceutical 
institutions. Naturally, mitochondria have long been known to be sensitive to many compounds and are also known to play 
important role in drug metabolism and are thus important targets for drug development (Manash et al., 2006). Mitochondrial 
uncouplers are compounds that uncouple mitochondrial substrate oxidation from ATP synthesis. By so doing, they increase 
substrate oxidation without the corresponding increase in ATP production (Nicholls, 1974a,b). Therefore, isolated 
mitochondria are said to be uncoupled, when there is oxygen consumption in absence of ATP synthesis either in presence of 
inhibitor of ATPase (oligomycin) or in absence of ADP that is state 4 respiration as opposed to state 3 respiration which is 
mitochondrial respiration in presence of ADP. Uncouplers work by transporting protons across the mitochondrial inner 
membrane short-circuiting the normal pathway of oxidative ATP synthesis driven by proton flow and causing the loss of 
calories as heat. 
         There are two sorts of uncoupling: Basal uncoupling is not acutely regulated and is present in all mitochondria and 
mainly a characteristic of the bilayer, whereas inducible proton conductance is catalysed by proteins, tightly regulated and 
found in discrete cell types. This suggest that uncouplers could be lipophilic weak acids that picks up protons from the 
cytosol, diffuse across the mitochondrial inner membrane into the matrix, deprotonate and then exit as anions before 
repeating the catalytic cycle; or activators of specific proteins with uncoupling action such as the uncoupling proteins and the 
adenine nucleotide translocase. Several of the lipophilic weak acid uncouplers are known. The most notable among them are 
DNP, cabonyl cyanide p-trifluoromethoxyphenylhydrazone, FCCP, carbonyl cyanide m-chlorophenylhydrazone, CCCP 
(Harper, 1965; Lou et al., 2007). However, very few of the activators of the protein catalysed pathway have been identified. 
They are fatty acids, which activate proton cycling through the uncoupling proteins, superoxides and 4-hydroxynonenal 
(HNE), which activate the UCPs and ANT.  
 
Plants as source of drugs 
 
         The importance of medicinal plants in the discovery of novel pharmaceuticals cannot be overemphasised and has been 
reviewed elsewhere (Lewis and Elvin-Lewis; 1995 Rates, 2001). The use of natural products with therapeutic properties is as 
ancient as human civilisation and, for a long time, mineral, plant and animal products were the main sources of drugs (see 
historical review by De Pasquale, 1984). Of the 252 drugs considered as basic and essential by the World Health 
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Organisation (WHO), 11% are exclusively of plant origin and a significant number are synthetic drugs obtained from natural 
precursors (Rates, 2001). According to Taylor, (2005), there are at least 120 distinct chemical substances derived from plants 
that are currently in use as important drugs in one or more countries in the world. In deed “nature has provided us with plants 
for food and medicine”. Natural compounds can be lead compounds, allowing the design and rational planning of new drugs, 
biomimetic synthesis development and the discovery of new therapeutic properties not yet attributed to known compounds 
(Hamburger and Hostettmann, 1991). 
         In the process of targeting plants for new therapeutics, evaluation of collected plants is one of the important steps 
(Lewis and Elvin-Lewis, 1995). This includes biodirected assays which are normally followed by chemical fractionations and 
characterisation. Therefore the study of the effects of extracts from Africa’s medicinal plants on mitochondrial substrate 
oxidation and membrane potential is essential to the discovery of novel anti-obesity mitochondrial uncouplers from Africa’s 
medicinal plants.  
 
Probing Africa’s Medicinal Plants 
 
         That there are novel natural uncouplers in Africa’s rich flora cannot be an overstatement. The onus is on Africa 
scientists in general and African Medicinal Plant Researchers in particular to conduct thorough research into identifying and 
characterising such compounds. Mitochondrial uncouplers cause increased oxygen consumption at same membrane potential 
resulting in a shift to the right of the proton leak curve providing a simple and less tedious diagnostic tool for identifying 
potential mitochondrial uncoupler. This simple procedure was recently explored by Lou et al. (2007), which led them to 
identifying uncouplers with extraordinary dynamic range. Therefore, studying the proton leak kinetics in different tissues in 
presence and absence of targeted plant extracts could provide a lead to discovering these important compounds.                       
   
Concluding Remarks 
 
         Mitochondria have long been known to be sensitive to many compounds and are also known to play important role in 
drug metabolism and are thus important targets for drug development. Mitochondrial uncouplers are potential anti-obesity 
agents. The search for these natural mitochondrial uncouplers has become a big challenge and of immense importance to 
biochemists and pharmacologists. Plants have always had the advantage of being cheap and important sources of drugs. 
Targeting mitochondrial uncoupling could produce a lead in discovering novel plant uncouplers with skeletal muscle specific 
action which could be developed into potent anti-obesity drug. 
 
 
Acknowledgements 
 
         The authors are grateful to the Office of Research and Innovation Development, University of Ghana for financial 
support from the University of Ghana Research Grant. 
 
 
References 
 
1. Blaxter K (1989). Energy Metabolism in Animals and Man. Cambridge University Press. 
2. Brand MD (1990). The contribution of the leak of protons across the mitochondrial inner membrane to standard 
metabolic rate. J. Theor. Biol. 145: 267-286. 
3. Brand MD (2005). The efficiency and plasticity of the mitochondrial energy transduction. Biochem. Soc. 33: 897- 904.  
4. Bray GA, Backburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, 
Scheinbaum ML, Seaton TB (1999) Sibutramine produces dose-related weight loss. Obes. Res. 7: 189-198. 
5. Clapham JC, Arch JR, Clapham H, Haynes A, Lister C, Moore GB, Piercy V, Carter SA, Lehner I, Smith SA, Beeley LJ, 
Godden RJ, Herrity N, Skehel M, Changani KK, Hockings PD, Reid DG, Squires SM, Hatcher J, Trial B, Latchman J, 
Rastan S, Harper AJ, Cadenas S, Buckingham JA, Brand MD, Abuin A (2000). Mice overexpressing human uncoupling 
protein-3 in skeletal muscle are hyperphagic and lean. Nature 406: 415-418. 
6. De Pasquale A (1984). Pharmacognosy: the oldest modern science. J. Ethnopharm. 11: 1–16. 
7. Ferro-Luzzi A, Martino L (1996). The origins and consequences of obesity, Wiley, Chichester. 
8. Hafner RP, Brown GC, Brand MD (1990). Thyroid-hormone control of state-3 respiration in isolated rat liver 
mitochondria. Biochem. J. 265:731-734.  
9. Hamburger M, Hostettmann K (1991). Bioactivity in plants: the link between phytochemistry and medicine. 
Phytochemistry 30(12): 3864–3874. 
 10. Harper JA, Dickinson K, Brand MD (2001). Mitochondrial uncoupling as a target for drug development for the treatment  
       of obesity. Obes. Rev. 2: 255-265. 
  11. Harper VH (1965). Uncouplers of rat liver mitochondrial oxidative phosphorylation. Biochem. J. 97: 658-662. 
  12. Hvizdos KM, Markham, A (1999) Orlistat: a review of its use in the management of obesity. Drugs 58: 743-760. 
  13. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF (2000). Effect of sibutramine  
        on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity  
        Reduction and Maintenance. Lancet. 356: 2119-2125. 
  14. Kennedy  E P, Lehninger A L (1949). Oxidation of fatty acids and tricarboxylic acid cycle intermediates by isolated rat 
         liver mitochondria. J. Biol. Chem. 179: 957-972. 
  15. Kopelman PG (2000). Obesity as a medical problem. Nature 404: 635-643 
Ocloo and Dongdem  Afr J Tradit Complement Altern Med. (2012) 9(2):256-259 
http://dx.doi.org/10.4314/ajtcam.v9i2.11 
 
259
15. Lewis WH, Elvin-Lewis MP (1995). Medicinal Plants as Sources of New Therapeutics, Ann. Missouri Bot. Gard. 82: 
16-24. 
  16. Li B, Nolte LA, Ju JS, Han DH, Coleman T, Holloszy JO, Semenkovich CF (2000). Skeletal muscle uncoupling  
      prevents diet-induced obesity and insulin resistance in mice. Nat. Med. 6: 1115-1120. 
  17. Lou P, Hansen BS, Olsen PH, Tullin S, Murphy MP, Brand MD (2007). Mitochondrial uncouplers with extraordinary  
         dynamic range. Biochem. J. 407: 129-140 
  18. Manash KP, Tripathy RK, Mukhopadhyay R, Mukhopadhyay AK (2006). Mitochondria - Role in different diseases:   
        potential for drug development. CRIPS. 7: 42-46. 
  19. Mitchell P (1961). Uncoupling of phosphorylation to electron and hydrogen transfer by a chemiosmotic type of  
        mechanism. Nature 191: 144-148. 
  20. Nicholls  DG (1974a). Hamster brown-adipose-tissue mitochondria. The control of respiration and the proton  
         electrochemical potential gradient by possible physiological effectors of the proton conductance of the inner membrane.  
         Eur. J. Biochem. 49: 573-583. 
  21. Nicholls  DG (1974b). The influence of respiration and ATP hydrolysis on the proton-electrochemical gradient across  
        the inner membrane of rat-liver mitochondria as determined by ion distribution. Eur. J. Biochem. 50: 305-315. 
  21. Parascandola J (1974). Dinitrophenol and bioenergetics: a historical perspective. Mol. Cell Biochem. 5: 69-77. 
  22. Poehlman ET (1989). A review: exercise and its influence on resting energy metabolism in man. Med. Sci. Sports Exerc.  
        21: 515-525.  
  23. Prentice, AM (2005). The emerging epidemic of obesity in developing countries. Int. J. Epidemiol. 35: 93-99. 
  24. Puhl R. and Brownell KD (2001). Bias. Discrimination, and Obesity. Obs. Res. 9: 788 – 805. 
  25. Rolfe DF, Brand MD (1996). Contribution of mitochondrial proton leak to skeletal muscle respiration and to standard 
         metabolic rate. Am. J. Physiol. 271, C1380-C1389. 
  26. Rolfe DF, Newman JM, Buckingham JA, Clark MG, Brand MD (1999). Contribution of mitochondrial proton leak to 
         respiration rate in working skeletal muscle and liver and to SMR. Am. J. Physiol. 276, C692-C699. 
  26. Ryan DH (2000). Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.  
        Endocrine 13: 193-199. 
  27. Rates SMK (2001). Plants as source of drugs. Toxicon. 39: 603-613. 
  28. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf  M (1998). Randomised placebo- 
        controlled trial of orlistat for weight loss and prevention of weight regain obese patients. European Multicentre Orlistat  
        Study Group. Lancet. 352: 167-172. 
29. Taylor L (2005). The healing powers of rainforest herbs. pp. Square one publishers Inc. New York. 
  30. Waden TA (1993). Treatment of obesity by moderate and severe caloric restriction: Results of clinical research trials.  
        Ann. Intern. Med. 119: 688-693 
   31. Weyer C, Gautier JF, Danforth E Jr (1999). Development of β3-adrenoceptor agonists for the treatment of obesity and  
          diabetes-an update. Diabetes Metab. 25: 11-21. 
 
 
